In R/R MCL, efficacy may come with trade-offs1

Treatment options have historically been limited1,2

CAR T doctor icon

Patients with MCL may relapse or become refractory after available therapies1,2

Mantle cell lymphoma medication icon

Response to therapy may continue to decline with subsequent lines of treatment3

MCL treatment icon

Most existing therapies still carry the burden of continuous treatment1

YOUR PATIENTS DESERVE MORE OPTIONS4

A powerful option with broad eligibility in 3L+ MCL

3L, third-line; CAR, chimeric antigen receptor; MCL, mantle cell lymphoma; R/R, relapsed or refractory.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.

References
  1. Burkart M, Karmali R. Relapsed/refractory mantle cell lymphoma: beyond BTK inhibitors. J Pers Med. 2022;12(3):376. doi:0.3390/jpm12030376
  2. Armitage JO, Longo DL. Mantle-cell lymphoma. N Eng J Med. 2022;386(26):2495-2506. doi:10.1056/NEJMra2202672
  3. Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(6):50. doi:10.1038/41408-019-0209-5
  4. Breyanzi [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2024.